Cut prices and stage a series of games! "Hospital Shandong" opened the drug belt volume procurement prologue!

On September 14, the Executive Meeting of the Shandong Provincial People's Government deliberated and adopted the Implementation Plan for the Centralized Belt Purchase of Pharmaceuticals and High-Value Medical Supplies in Shandong Province.
The Program, in accordance with the requirements of "belt procurement, recruitment, quality priority, ensure dosage and guarantee return", implements centralized belt procurement of medicines and high-value medical supplies, guides pharmaceutical enterprises to compete fairly, and effectively reduces the burden of medical expenses for the masses.
October 11, Shandong Province drug belt procurement documents officially issued, the first batch of 40 drug varieties, covering cardiovascular, digestive, respiratory, tumor and other clinical disciplines.
From a national perspective, the largest number of provincial-level projects in the national provincial procurement of one-time centralized procurement of drugs first under the National Day before the Guangxi Pharmaceutical Group procurement, the number of up to 100 varieties, in addition to Shandong's 40 varieties ranked second.
according to the Ministry of Commerce's statistical analysis of drug circulation industry operations, Shandong's total sales in 2017 amounted to 114.39 billion yuan.
not dispute the grouping, divided into two groups.
Expired patents, participation, evaluation, evaluation, evaluation, listing catalog set and by the United States, Japan, Britain, Germany, France, Australia, plus seven countries certification, products in the first group, other imported drugs, domestic imitation drugs in the second group.
This grouping, basically followed the current provincial collection of the general route, that is, the original quality level evolved into a bidding group, a group of basic to the original research, evaluation, as the same evaluation-based, a group of generic drugs and imported drugs mainly.
, an expert in pharmaceutical policy in the pharmaceutical industry, believes that the group presents a feature of both controlled products, while some products do not have the original research and participation, while some products have dual-participation.
the first group is less pressure, the second group of competitive pressure is high.
is clearer in terms of the varieties to be selected.
comprehensive evaluation in the evaluation groups of 3 or more enterprises that are required to declare.
For each variety to enterprise quotations, procurement volume ratio, medical institutions coverage and other factors for comprehensive evaluation, the proportion of points is 60%, 20%, 20%, the three points added to the comprehensive evaluation score (the second evaluation group won the second prize of the National Science and Technology Progress Award and above drugs plus 0.5 points).
fully competitive products still basically follow the 7th text double envelope mixed entry mechanism, but on this basis, the price achieved organic unity. the
document emphasizes that according to the declared enterprise declaration varieties of their respective comprehensive evaluation score from high to low to determine 2 shortlisted enterprises, and the lowest price among the shortlisted enterprises as the evaluation group in the selection price, the lowest quotation shortlisted enterprises for the first place in the evaluation group to be selected enterprises.
the same as the quotation of the shortlisted enterprises, the enterprises with higher comprehensive scores are the first enterprises to be selected.
the author reminds you that the emphasis here is on the number of shortlisted enterprises and the relationship between the selected price.
, the selected enterprises are considering the comprehensive evaluation score.
, look only at the top two companies.
second, once two enterprises are selected, at this time no longer look who score high and who score low, but look at the two enterprises who have the lowest price.
That is to say, from the actual situation, to the comprehensive evaluation score of the first selected enterprises, due to the high price, it will be likely to be overtaken by the second place, replaced as the first selected enterprise of the review group.
In the evaluation group of 2 declared enterprises, the proportion of procurement volume, the coverage of medical institutions for comprehensive evaluation, the proportion of points is 20%, 20%, the two points add up to a comprehensive evaluation score (the second evaluation group won the second prize of the National Science and Technology Progress Award and above drugs plus 0.5 points).
because the declared enterprises for 2 are already not fully competitive products, therefore, only the evaluation of economic and technical standards, the comprehensive evaluation score directly into the business standards.
the highest score, the hardest to kill.
the process of entering the bargaining process, in accordance with the order of comprehensive evaluation score from high to low, and the declared enterprises to bargain.
enterprise with a high score reaches the relevant two conditions, it shall be determined as the first enterprise to be selected, and the bargaining price shall be the selected price in the evaluation group, and if it is not reached, it shall be regarded as giving up.
overall, for under-competitive varieties, the fate of the decline is not in their own hands, but in the hands of fully competitive varieties.
the price of the first position depends on the price of the second down the original hanging net price, the same, the fate of the second down position is the same.
the evaluation group of 1 declared enterprise, the proposed enterprise is determined by bargaining.
(the proportion of procurement volume, medical institutions coverage is no longer the focus of the evaluation, directly omitted), accept the same level of evaluation group, 3 or more reporting enterprises review group generated by the average decline in the average price of the selected price or "all the evaluation group, 3 and above of the reporting enterprise evaluation group generated by the average decline in the average price of the selection" One of the conditions, for the review group to choose enterprises, do not accept the same as give up: the author believes that this seems to give two drops to choose, but in fact, a cross-wood respect one and a cross-wood respect two, both are ultra-low or new low, enterprises can only be low in the middle election higher.
but from the assessment point of view of quantity, the document gives the temptation of quantity, that is, choose a higher decline, give 70%, choose a lower decline, give 60%.
(nitrobenzene flat-controlled release dosage form, tekmos oral normal release dosage form slightly analyzed).
the document does not make a detailed distinction between the procurement volume of the first and second groups, and the bidding enterprises should focus on the division of quantities.
, the document states that during the procurement cycle, medical institutions should give priority to the use of selected drugs in the centralized procurement of the drug and ensure the completion of the agreed procurement volume.
the remaining dosing can be purchased in moderant quantities with the same variety price of other hanging-up drugs.
to the enterprises concerned, from the price, product regulations and even health insurance perspective to consider, once the bid how to deal with.
.